Literature DB >> 14648446

Harm reduction actions as a health care construction process at a public health center in Rosario, Argentina.

Damián Lavarello1, Miguel Lottero, Mario Chavero, Alejandra Toledo, Mario Espínola, Sandra Gerlero, Mónica Liborio.   

Abstract

Even faced with serious numbers of human immunodeficiency virus (HIV) and other infections among injection drug users (IDUs), Argentina lacks large-scale harm reduction programs at national, state, and local levels. We describe the strong relationship of IDUs with the HIV/acquired immunodeficiency syndrome epidemic in Rosario. We discuss a 2-year-long ongoing experience of drug-related harm reduction actions developed at a public health center, which began as a response to a spontaneous demand for needles and syringes and became a permanent and sustainable set of health actions for a group of nearly 50 IDUs, a larger number of drug users who do not inject, and their contacts. These actions comprise voluntary testing and counseling for HIV and other infections, reproductive counseling, condom promotion and distribution, and needle and syringe distribution without needle exchange. This experience, amenable to replication, shows that public health teams can engage successfully in harm reduction actions.

Entities:  

Mesh:

Year:  2003        PMID: 14648446     DOI: 10.1086/377545

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  2 in total

1.  Congregational involvement in HIV: A qualitative comparative analysis of factors influencing HIV activity among diverse urban congregations.

Authors:  Peter Mendel; Harold D Green; Kartika Palar; David E Kanouse; Ricky N Bluthenthal; Michael A Mata; Clyde W Oden; Kathryn P Derose
Journal:  Soc Sci Med       Date:  2019-12-05       Impact factor: 4.634

Review 2.  Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control.

Authors:  Catherine S Todd; Bijan Nassiramanesh; Mohammad Raza Stanekzai; Adeeba Kamarulzaman
Journal:  Curr HIV/AIDS Rep       Date:  2007-12       Impact factor: 5.495

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.